ALK (R1275Q)
Sign in to save this workspaceALK · Variant type: point · HGVS: p.R1275Q
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 99.8% | 0.3% | 88.97 |
| 2 | Repotrectinib | 99.7% | 0.3% | 84.21 |
| 3 | Entrectinib | 99.5% | 0.5% | 93.69 |
| 4 | Lorlatinib | 98.6% | 1.4% | 97.24 |
| 5 | Crizotinib | 98.5% | 1.5% | 91.39 |
| 6 | Brigatinib | 97.9% | 2.1% | 82.96 |
| 7 | Alectinib | 96.0% | 4.0% | 95.49 |
| 8 | Pralsetinib | 92.3% | 7.7% | 93.43 |
| 9 | Sunitinib | 90.8% | 9.2% | 91.73 |
| 10 | Nintedanib | 90.4% | 9.6% | 90.23 |
| 11 | Alpelisib | 89.4% | 10.6% | 97.22 |
| 12 | Ceritinib | 89.3% | 10.7% | 95.44 |
| 13 | Osimertinib | 85.8% | 14.2% | 97.24 |
| 14 | Bosutinib | 82.2% | 17.8% | 87.22 |
| 15 | Lazertinib | 68.2% | 31.8% | 97.47 |
| 16 | Pacritinib | 66.5% | 33.5% | 88.64 |
| 17 | Cabozantinib | 58.4% | 41.6% | 92.73 |
| 18 | Ruxolitinib | 56.2% | 43.8% | 98.25 |
| 19 | Defactinib | 55.6% | 44.4% | 92.68 |
| 20 | Tenalisib | 53.7% | 46.3% | 97.98 |
| 21 | Fedratinib | 52.3% | 47.7% | 96.21 |
| 22 | Fostamatinib | 49.1% | 50.9% | 96.74 |
| 23 | Ponatinib | 39.2% | 60.8% | 78.23 |
| 24 | Baricitinib | 38.9% | 61.1% | 97.99 |
| 25 | Neratinib | 38.5% | 61.5% | 93.18 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 99.8% | 99.5% | +0.3% |
| Repotrectinib | 99.7% | 99.4% | +0.3% |
| Entrectinib | 99.5% | 98.8% | +0.7% |
| Lorlatinib | 98.6% | 97.2% | +1.4% |
| Crizotinib | 98.5% | 97.7% | +0.7% |
| Brigatinib | 97.9% | 99.2% | -1.3% |
| Alectinib | 96.0% | 98.6% | -2.5% |
| Pralsetinib | 92.3% | 82.6% | +9.7% |
| Sunitinib | 90.8% | 87.7% | +3.2% |
| Nintedanib | 90.4% | 84.9% | +5.5% |
| Alpelisib | 89.4% | 80.7% | +8.7% |
| Ceritinib | 89.3% | 98.3% | -8.9% |
| Osimertinib | 85.8% | 80.5% | +5.3% |
| Bosutinib | 82.2% | 75.1% | +7.1% |
| Lazertinib | 68.2% | 46.3% | +22.0% |
| Pacritinib | 66.5% | 55.3% | +11.2% |
| Cabozantinib | 58.4% | — | — |
| Ruxolitinib | 56.2% | 52.1% | +4.2% |
| Defactinib | 55.6% | — | — |
| Tenalisib | 53.7% | 45.2% | +8.5% |
| Fedratinib | 52.3% | — | — |
| Fostamatinib | 49.1% | — | — |
| Ponatinib | 39.2% | — | — |
| Baricitinib | 38.9% | 46.4% | -7.5% |
| Neratinib | 38.5% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| Neuroblastoma | Brain/CNS | ref |
| neuroblastoma_autonomic_ganglia | Brain/CNS | ref |
| carcinoma_large_intestine | Large Intestine | ref |
| carcinoma_prostate | Prostate | ref |
| ganglioneuroblastoma_autonomic_ganglia | Brain/CNS | ref |
| carcinoma_breast | Breast | ref |
| thymic_carcinoma_thymus | Thyroid | ref |
| COCA-CN | Large Intestine | ref |
| NBL-US | Brain/CNS | ref |
| NB | Brain/CNS | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 29.1ms